Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
P3.12.69 Updated Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: Phase 2 TRUST-I Study
2025
1 citations
Journal Article
Field-Weighted Citation Impact:
1.65
·
Shandong First Medical University
Boyang Jason Wu
·
First Affiliated Hospital of Xiamen University
Zhen Wang
·
Peking University Cancer Hospital
Yunpeng Liu
·
China Medical University
Xingliang Qin
·
First Affiliated Hospital of Guangdong Pharmaceutical University
Kaihua Lu
·
Jiangsu Province Hospital
Wei Zhuang
·
Fujian Provincial Cancer Hospital
Yizhong Ren
·
Nuvotronics (United States)
XingYa Li
·
Nuvotronics (United States)
Ran Fei
·
Nuvotronics (United States)
Caicun Zhou
·
Shanghai East Hospital
P3.12.69 Updated Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: Phase 2 TRUST-I Study | Researchclopedia